hallmark
translat
human
immunodefici
viru
type
program
ribosom
frameshift
event
produc
gagpol
fusion
polyprotein
constant
gag
gagpol
ratio
essenti
virion
structur
infect
show
frameshift
effici
modul
leutrna
leu
read
uua
codon
mrna
slipperi
site
trna
leu
isoacceptor
particularli
rare
human
cell
line
deriv
tlymphocyt
cell
target
uua
decod
delay
frameshift
follow
altern
rout
maintain
gag
gagpol
ratio
constant
second
potenti
slipperi
site
downstream
first
one
normal
ineffici
also
support
alter
compensatori
resist
mutat
respons
current
antivir
drug
therapi
togeth
differ
regim
allow
viru
maintain
constant
effici
ensur
success
viru
propag
figur
gagpol
mrna
scheme
gagpol
frameshift
site
slipperi
site
put
second
slipperi
site
highlight
green
stimulatori
mrna
structur
element
downstream
indic
stemloop
amino
acid
incorpor
peptid
well
potenti
rout
vivo
effici
shown
frameshift
site
b
top
panel
amino
acid
incorpor
shown
mrna
sequenc
bottom
panel
effici
wildtyp
wt
mrna
u
c
deriv
disrupt
measur
limit
amount
leutrna
naa
leu
molar
ratio
trna
ribosom
end
translat
min
sum
mqanf
mqanflg
peptid
correspond
mqanffrflr
peptid
mqanf
identifi
base
posit
chromatogram
mqanffrflr
mqanflg
product
quantifi
use
c
arg
h
gli
respect
c
concentr
depend
effici
leutrna
naa
leu
trna
naa
leu
close
circl
mixtur
trna
leu
isoacceptor
read
cun
codon
trna
nag
leu
open
circl
product
detect
use
c
arg
chang
fs
regim
leutrna
naa
leu
concentr
ratio
ffr
rout
open
circl
versu
flr
close
circl
rout
calcul
peptid
differ
radioact
label
follow
sum
ffr
flr
frameshift
product
calcul
use
c
arg
determin
amount
flr
mrna
translat
peptid
fmetglnasnpheleuglylysil
mqanflgki
presenc
ile
allow
separ
mqanflgki
mqanflr
peptid
ffr
peptid
determin
subtract
flr
total
argcontain
product
e
effici
presenc
vari
concentr
glytrna
gli
presenc
excess
argtrna
arg
green
squar
vari
concentr
argtrna
arg
presenc
glytrna
gli
red
light
red
squar
respect
mani
virus
use
program
ribosom
frameshift
increas
code
capac
genom
regul
stoichiometr
ratio
viral
protein
two
gene
gag
pol
encod
viral
structur
protein
enzym
respect
overlap
nt
synthesi
gagpol
polyprotein
requir
ribosom
frameshift
ratio
gag
gagpol
crucial
viru
propag
dysregul
detriment
replic
virion
format
infect
effici
gagpol
human
cell
rang
differ
report
effici
recapitul
vivo
vitro
mammalian
yeast
escherichia
coli
translat
extract
suggest
viru
exploit
evolutionari
conserv
featur
translat
apparatu
govern
two
cisact
element
mrna
slipperi
site
u
uuu
uua
encod
phe
uuu
leu
uua
stemloop
sl
structur
downstream
slipperi
site
figur
give
rise
two
frameshift
product
one
contain
peptid
pheleu
follow
sequenc
flr
product
figur
b
anoth
second
phe
incorpor
instead
leu
ffr
product
mammalian
cell
frameshift
ribosom
insert
leu
like
insert
phe
posit
also
e
coli
product
produc
flr
constitut
product
hiv
frameshift
product
heterogen
may
result
frameshift
addit
gagpol
gene
second
put
slipperi
site
nt
downstream
canon
slipperi
site
also
conserv
albeit
lesser
degre
first
slipperi
site
sequenc
u
uuu
cuu
particularli
slipperi
substitut
c
u
c
u
appear
compensatori
resist
mutat
antihiv
therapi
may
facilit
addit
fs
otherwis
silent
site
mechan
frameshift
gagpol
mrna
factor
defin
ratio
two
product
unclear
varieti
propos
mechan
uncertain
signific
second
slipperi
site
lack
mechanist
inform
altern
slippag
eg
prompt
us
studi
gagpol
frameshift
real
time
fulli
reconstitut
vitro
translat
system
show
fs
pathway
effici
determin
avail
leutrna
leu
read
uua
codon
potenti
altern
slippag
also
oper
aminoacyltrna
aatrna
limit
suppli
show
uuaspecif
trna
leu
particularli
rare
human
cell
line
deriv
tlymphocyt
cell
target
furthermor
character
role
second
slipperi
site
support
multipl
way
modul
frameshift
effici
could
help
viru
maintain
gag
gagpol
ratio
crucial
viabil
experi
prokaryot
translat
compon
includ
kinet
measur
summar
supplementari
tabl
carri
hifi
buffer
mm
trishcl
ph
mm
nh
cl
mm
kcl
mm
mgcl
mm
putrescin
mm
spermidin
mm
dtt
c
state
otherwis
ribosom
e
coli
initi
factor
elong
factor
eftu
efg
fmettrna
fmet
bodipymettrna
fmet
phetrna
phe
prepar
e
coli
describ
gln
alaand
asntrna
mixtur
argtrna
arg
glytrna
gli
valtrna
val
prepar
e
coli
total
trna
aminoacyl
respect
amino
acid
subsequ
affin
chromatographi
eftugtpaatrna
ternari
complex
protino
niida
pack
column
machereynagel
follow
phenol
ethanol
precipit
aatrna
trna
naa
leu
elong
trna
met
trna
tyr
mixtur
isoacceptor
trna
leu
collect
read
four
cun
codon
leu
prepar
consecut
column
chromatographi
sepharos
ge
healthcar
phenyl
sepharos
ge
healthcar
deae
toyopearl
tosoh
bioscienc
trna
trp
prepar
rnapolymeras
transcript
plasmid
carri
e
coli
trp
gene
trna
charg
c
hlabel
unlabel
amino
acid
leutrna
naa
leu
mixtur
isoacceptor
leutrna
cun
codon
mettrna
e
met
iletrna
ile
tyrtrna
tyr
purifi
reversedphas
hplc
column
mm
mm
merck
equilibr
mm
ammonium
acet
ph
mm
magnesium
acet
mm
nacl
use
gradient
ethanol
concentr
determin
spectrophotometr
nm
liquidliquid
scintil
count
applic
ultima
gold
xr
perkin
elmer
total
human
aatrna
prepar
hela
cell
extract
cytoplasm
fraction
cell
lysat
phenol
aatrna
purifi
anionexchang
chromatographi
hitrap
q
hp
column
ml
ge
healthcar
equilibr
mm
sodium
acet
ph
mm
mgcl
use
gradient
kcl
use
nativ
sequenc
gagpol
frameshift
motif
nt
complet
genom
ncbi
refer
sequenc
nc
clone
vector
mutat
introduc
sitedirect
mutagenesi
use
dnapolymeras
neb
supplementari
tabl
mrna
prepar
vitro
transcript
rnapolymeras
purifi
use
rneasi
maxi
kit
qiagen
accord
manufactur
recommend
control
mrna
use
determin
rate
argtrna
arg
incorpor
supplementari
figur
made
chemic
synthesi
iba
contain
e
coli
shinedalgarno
sd
sequenc
insert
nt
upstream
start
codon
aug
translat
bacteri
translat
system
sd
sequenc
insert
hiv
mrna
nt
upstream
start
codon
aug
short
mrna
use
codon
walk
experi
aug
introduc
nt
upstream
length
sequenc
follow
nt
encompass
mrna
use
studi
frameshift
ggg
codon
gli
follow
slipperi
site
mutat
ugg
trp
distinguish
product
nearest
natur
aug
gag
mrna
use
start
codon
long
mrna
studi
gagpol
translat
product
page
stop
codon
uag
introduc
nt
downstream
aug
nt
allow
separ
aa
aa
product
control
mrna
contain
respect
sequenc
clone
infram
mutat
prevent
slippag
mrna
contain
nt
harbor
hiv
mrna
eukaryot
translat
contain
nativ
utr
rabbit
mrna
kozak
sequenc
embed
augg
site
allow
effici
initi
start
codon
aug
place
nt
upstream
slipperi
site
next
codon
cag
gln
mutat
gag
val
improv
initi
facilit
product
separ
hplc
eukaryot
mrna
contain
nt
downstream
cover
mrna
sequenc
list
supplementari
tabl
aug
bold
slipperi
site
underlin
uag
stop
codon
ital
mutat
nucleotid
small
letter
bold
form
eftugtpaatrna
ternari
complex
tc
eftu
excess
aatrna
incub
gtp
mm
phosphoenolpyruv
mm
pyruv
kinas
mgml
buffer
dtt
mm
min
c
aatrna
ad
incub
min
c
concentr
aatrna
optim
ensur
maximum
bind
respect
codon
glntrna
gln
alatrna
ala
asntrna
asn
phetrna
phe
argtrna
arg
glytrna
gli
differ
concentr
leutrna
naa
leu
indic
ic
mix
tc
final
concentr
eftu
efg
gtp
mm
phosphoenolpyruv
mm
pyruv
kinas
mgml
hifi
buffer
c
incub
time
min
time
cours
min
endpoint
measur
stabil
peptidyltrna
bind
ribosom
test
nitrocellulos
filter
bind
assay
supplementari
figur
prepar
sampl
hplc
analysi
reaction
quench
koh
hydrolyz
min
c
sampl
neutral
addit
acet
acid
translat
product
separ
reversedphas
hplc
column
merck
appli
adapt
gradient
acetonitril
trifluoroacet
acid
elut
fraction
mix
ultima
gold
xr
scintil
liquid
perkin
elmer
analyz
scintil
count
peptid
product
mqan
separ
peptid
could
identifi
either
posit
shift
chromatogram
radioact
label
respect
amino
acid
amount
product
determin
ratio
hcount
respect
peak
total
hcount
eluat
sampl
h
glytrna
gli
c
argtrna
arg
c
leu
trna
naa
leu
respect
peak
calcul
pmol
necessari
amount
mqanflr
peptid
calcul
subtract
mqanflg
mqanfl
pmol
likewis
mqanffr
peptid
calcul
subtract
mqanflr
mqanflrffr
mixtur
product
pmol
time
cours
evalu
numer
integr
kintek
explor
softwar
frameshift
effici
calcul
ratio
peptid
mqanffr
mqanflr
sum
peptid
mqanf
mqanfl
mqanflg
multipli
translat
mrna
carri
describ
codonwalk
assay
glntrna
gln
alatrna
ala
asntrna
asn
prepar
sampl
page
reaction
stop
naoh
hydrolyz
describ
hplc
sampl
prepar
hepe
ph
ad
neutral
reaction
sampl
separ
tristricin
gel
electrophoresi
fluoresc
peptid
visual
use
scanner
ge
healthcar
life
scienc
band
intens
evalu
use
multigaug
softwar
frameshift
effici
calcul
band
intens
product
sum
product
well
translat
intermedi
appear
translat
correct
length
peptid
confirm
use
control
mrna
ribosom
subunit
hela
translat
initi
factor
translat
elong
factor
well
mettrna
met
prepar
accord
publish
protocol
figur
h
arg
radioact
label
start
translat
equal
volum
elong
reaction
mix
ad
initi
reaction
mix
incub
min
c
sampl
prepar
hplc
hplc
analysi
quantif
radioact
peptid
done
describ
bacteri
translat
system
peptid
identifi
base
h
arg
presenc
leu
total
translat
effici
quantifi
use
c
leu
frameshift
effici
calcul
ratio
argcontain
peptid
total
translat
product
multipli
absenc
leu
total
translat
effici
calcul
use
control
show
maximum
level
frameshift
peptid
produc
given
condit
frameshift
effici
calcul
ratio
argcontain
wt
peptid
control
peptid
multipli
jurkat
nih
aid
reagent
program
maintain
roswel
park
memori
institut
medium
rpmi
pan
biotech
supplement
fc
concentr
penstrep
mix
subcultur
cultur
medium
contain
suspens
cell
centrifug
g
min
room
temperatur
supernat
discard
pellet
cell
resuspend
ml
rpmi
medium
ml
suspens
ad
new
cultur
flask
fill
ml
rpmi
medium
cellular
trna
level
trna
uaa
leu
trna
cag
leu
trna
uac
val
trna
cac
val
quantifi
use
strategi
publish
total
cellular
rna
extract
use
rneasi
mini
kit
qiagen
accord
manufactur
protocol
elut
rna
content
determin
spectrophotometr
elimin
potenti
coisol
dna
sampl
g
rna
incub
dnase
new
england
biolab
final
volum
l
min
c
final
heat
c
min
inactiv
enzym
primer
revers
transcript
entail
trnaspecif
sequenc
stemloop
sequenc
trnaspecif
primer
trna
uaa
leu
trna
cag
leu
complementari
posit
first
aim
solv
mechan
mrna
mechanist
work
use
fulli
reconstitut
translat
system
e
coli
overal
effici
ratio
flr
ffr
product
similar
mammalian
cell
e
coli
function
center
ribosom
frameshift
take
place
highli
conserv
eukaryot
prokaryot
feasibl
prepar
materi
reconstitut
eukaryot
translat
system
amount
need
type
analysi
first
test
potenti
rout
frameshift
model
gagpol
mrna
encompass
natur
frameshift
site
translat
start
codon
aug
three
codon
upstream
slipperi
site
figur
form
initi
complex
mrna
fmettrna
fmet
start
translat
addit
ternari
complex
elong
factor
ef
tugtp
desir
combin
purifi
aatrna
efggtp
consecut
amino
acid
incorpor
result
peptid
fmetglnalaasnpheleugli
mqanflg
peptid
fmetglnalaasnpheleuarg
mqanflr
fmetglnalaasnphephearg
mqanffr
peptid
analyz
reversedphas
hplc
rphplc
supplementari
figur
overal
frameshift
effici
determin
yield
arg
incorpor
rel
sum
peptid
mrna
contain
nativ
slipperi
sequenc
larg
fraction
peptid
contain
arg
figur
indic
effici
expect
u
c
mutat
chang
sequenc
u
uuc
uua
abolish
fs
figur
supplementari
figur
principl
occur
decod
step
translat
elong
cycl
peptidyltrna
bound
p
site
ribosom
site
vacant
transloc
two
trna
togeth
mrna
move
ribosom
slippag
occur
decod
effici
must
depend
competit
aatrna
leutrna
phetrna
bind
uuua
sequenc
fact
addit
leutrna
naa
leu
e
coli
trna
read
uua
uug
codon
anticodon
indic
subscript
n
posttranscript
modifi
nucleotid
dramat
lower
effici
absenc
presenc
leutrna
naa
leu
figur
contrast
mixtur
nearcogn
leutrna
isoacceptor
collect
read
cun
famili
leu
codon
effect
high
effici
observ
absenc
leutrna
naa
leu
indic
ribosom
slip
prior
independ
leu
incorpor
estim
ratio
leu
phe
arg
incorpor
product
determin
pathway
chang
leutrna
naa
leu
concentr
figur
absenc
leutrna
naa
leu
ffr
product
form
upon
addit
leutrna
naa
leu
flr
product
becom
preval
thu
frameshift
gagpol
slipperi
site
switch
two
regim
preval
depend
concentr
critic
trna
leu
incorpor
follow
differ
rout
take
place
either
trna
leu
transloc
upon
decod
follow
gli
codon
frameshift
took
place
decod
glytrna
gli
argtrna
arg
compet
bind
ribosom
howev
observ
effici
independ
glytrna
gli
argtrna
arg
concentr
figur
find
suggest
slippag
commit
new
read
frame
occur
leu
incorpor
prior
decod
next
codon
glyor
argtrna
similar
wellstudi
case
ibv
dnax
mrna
slippag
occur
late
stage
transloc
slipperysit
trna
suggest
similar
twotrna
frameshift
mechan
uua
codon
particularli
rare
human
cell
respect
leutrna
naa
leu
underrepres
cell
type
see
format
ffr
product
depend
slippag
hungri
uua
codon
test
whether
allow
also
note
normal
slippag
event
would
lead
prematur
termin
due
stop
codon
appear
frame
downstream
frameshift
site
peptid
difficult
detect
vivo
altern
slippag
event
could
chang
ratio
gag
gagpol
polyprotein
distinguish
product
chang
ggg
gli
codon
follow
slipperi
site
ugg
trp
figur
supplementari
figur
mutat
affect
effici
vivo
human
cell
addit
aatrna
need
translat
mqanfl
sequenc
ad
purifi
trptrna
trp
w
elong
mettrna
met
tyrtrna
tyr
expect
peptid
mqanflw
peptid
mqanffm
mqanflm
shift
yield
mqanfi
mqanffi
mqanfli
requir
aatrna
present
peptid
account
product
consist
effici
nativ
gagpol
sequenc
presenc
equimolar
amount
leutrna
naa
leu
ribosom
figur
wherea
amount
peptid
small
mettrna
met
omit
increas
wherea
chang
enhanc
expos
hungri
met
codon
site
favor
slippag
absenc
leuand
trptrna
effici
increas
expect
unchang
small
amount
product
form
without
addit
leu
trpand
mettrna
product
three
altern
frame
found
data
suggest
occur
one
aatrna
lack
howev
aatrna
avail
pathway
preval
understand
kinet
switch
two
differ
regim
monitor
translat
effici
use
codonwalk
approach
absenc
presenc
leutrna
naa
leu
rate
constant
calcul
global
fit
time
cours
use
numer
integr
accord
model
shown
figur
addit
inform
estim
rate
constant
arg
gli
incorpor
independ
experi
use
model
mrna
without
frameshift
element
supplementari
figur
c
model
absenc
leutrna
naa
leu
introduc
step
result
format
mqanf
product
mqanff
mqanffr
addit
introduc
two
reaction
branch
account
incomplet
convers
ic
product
follow
fraction
initi
complex
enter
translat
introduc
step
account
unproduct
popul
n
nonreact
also
notic
mqanftrna
phe
absenc
asit
ligand
tend
slowli
dissoci
ribosom
supplementari
figur
account
loss
peptidyltrna
introduc
respect
dropoff
reaction
global
fit
time
cours
use
numer
integr
yield
uniqu
solut
rate
constant
figur
b
supplementari
tabl
step
lead
incorpor
second
phe
slow
compar
translat
step
least
time
faster
mqanff
peptid
accumul
convert
peptid
mqanffr
thu
incorpor
second
phe
residu
ratelimit
step
frameshift
commit
ribosom
translat
presenc
leutrna
naa
leu
ribosom
synthes
mqanf
peptid
either
continu
translat
leu
incorpor
shift
leutrna
naa
leu
bind
leu
incorpor
mqanfl
product
partit
mqanflg
mqanflr
global
fit
time
cours
give
welldefin
rate
constant
step
figur
ratelimit
step
ffr
pathway
rate
constant
similar
isol
ffr
pathway
effici
ffr
pathway
depend
ratio
rate
leutrna
naa
leu
bind
rate
slippag
constant
rate
leutrna
naa
leu
bind
increas
concentr
explain
addit
excess
leutrna
naa
leu
inhibit
ffr
rout
high
concentr
leutrna
naa
leu
probabl
bind
leutrna
naa
leu
site
higher
slip
frame
condit
ffr
pathway
suppress
flr
pathway
remain
oper
leu
incorpor
effici
flr
rout
de
plot
ratio
trna
cag
leu
trna
uaa
leu
red
bar
trna
cac
val
trna
uac
val
blue
bar
read
frequent
rare
codon
respect
human
cell
line
error
bar
repres
sem
three
biolog
replic
three
technic
replic
experiment
design
qrtpcr
accord
human
cell
line
indic
graph
jurkat
deriv
human
tlymphocyt
btlymphocyt
fusion
hela
deriv
cervic
epitheli
carcinoma
kidney
epitheli
cell
line
fine
transloc
step
partit
take
place
decod
glyand
argtrna
figur
ratio
rate
constant
gli
arg
incorpor
respect
supplementari
tabl
give
effici
leu
incorpor
find
leutrna
leu
isoacceptor
read
uua
codon
affect
mechan
effici
prompt
us
valid
key
result
eukaryot
system
first
analyz
rel
abund
human
leutrna
leu
read
uua
codon
trna
uaa
leu
total
trna
differ
human
cell
type
use
qrtpcr
figur
mainli
infect
tlymphocyt
macrophag
determin
ratio
leutrna
uaa
leu
leutrna
cag
leu
read
abund
leu
codon
cug
leutrna
uaa
leu
less
abund
leutrna
cag
leu
cell
line
deriv
lymphocyt
hela
cell
wherea
type
human
cell
ratio
figur
leutrna
uaa
leu
concentr
vari
much
wherea
leutrna
cag
leu
differ
smaller
except
hela
cell
leutrna
cag
leu
concentr
increas
supplementari
figur
control
quantifi
rel
abund
valtrna
val
isoacceptor
read
rare
gua
codon
abund
gug
codon
trna
uac
val
isoacceptor
read
rare
codon
time
less
abund
common
trna
cac
val
except
epitheli
cell
amount
trna
uac
val
even
lower
figur
rel
abund
trna
uaa
leu
hela
cell
similar
cell
use
model
hiv
infect
use
total
human
trna
purifi
hela
cell
vitro
translat
experi
describ
first
test
hela
aatrna
perform
translat
combin
eftu
ribosom
e
coli
supplementari
figur
c
conform
human
aatrna
codon
usag
mammalian
mrna
valid
translat
mrna
code
bovin
bcrystallin
codon
usag
bcrystallin
match
trna
abund
eukaryot
host
e
coli
nativ
human
aatrna
bcrystallin
mrna
translat
effici
supplementari
figur
introduc
synonym
mutat
mrna
match
codon
usag
e
coli
reduc
yield
fulllength
product
supplementari
figur
averag
translat
rate
gagpol
nativ
bcrystallin
mrna
system
aa
supplementari
figur
translat
gagpol
mrna
fragment
encompass
region
nearest
nativ
elong
aug
codon
gag
mrna
upstream
downstream
second
put
fs
site
downstream
sequenc
predict
form
sl
figur
distinguish
translat
product
introduc
stop
codon
uag
obtain
peptid
amino
acid
aa
length
result
peptid
product
identifi
potenti
product
mutat
nativ
stop
codon
downstream
mrna
denot
nostop
translat
nostop
mrna
leav
product
length
unchang
addit
yield
product
despit
ident
length
product
differ
electrophoret
mobil
due
differ
amino
acid
composit
figur
supplementari
figur
effici
nativ
gagpol
frameshift
sequenc
figur
e
consist
earlier
invivo
report
format
product
start
delay
may
caus
earli
translat
paus
event
appear
promin
peptid
band
translat
figur
c
supplementari
figur
contrast
product
appear
much
longer
delay
time
synthesi
product
alreadi
complet
ribosom
suggest
may
aris
fraction
ribosom
undergo
long
translat
paus
addit
exogen
leutrna
naa
leu
decreas
effici
figur
supplementari
figur
similarli
reduc
fs
effici
observ
uua
codon
mutat
uuc
interrupt
slipperi
run
six
us
chang
ident
trna
read
second
slipperi
codon
abund
trna
phe
figur
thu
reassign
second
codon
slipperi
site
abund
trna
effect
ad
excess
trna
naa
leu
nativ
sequenc
shorten
slipperi
site
four
u
residu
decreas
fs
disrupt
alon
togeth
diminish
fs
effici
background
level
experi
figur
supplementari
figur
final
test
whether
addit
leutrna
uaa
leu
alter
frameshift
effici
homolog
reconstitut
mammalian
translat
system
ribosom
subunit
initi
factor
mettrna
use
form
initi
complex
mrna
un
figur
synthes
mvanflg
mvanflr
peptid
use
trna
hela
cell
aminoacyl
mixtur
requir
amino
acid
without
leu
incorpor
arg
monitor
hplc
analysi
supplementari
figur
control
includ
mrna
code
mvanflr
control
provid
estim
maximum
arg
incorpor
mrna
without
control
effici
fulli
reconstitut
eukaryot
translat
system
presenc
nativ
amount
trna
uaa
leu
figur
supplementari
figur
leucin
omit
aminoacyl
mixtur
effici
increas
figur
thu
leutrna
uaa
leu
modul
effici
hiv
mrna
also
homolog
mammalian
translat
system
test
effect
mutat
put
slipperi
sequenc
introduc
mutat
make
either
less
slipperi
figur
supplementari
figur
long
sequenc
un
figur
interplay
sequenc
shown
bar
sequenc
indic
graph
determin
wt
mrna
black
bar
nostop
mrna
gray
bar
measur
nostop
mrna
white
bar
absenc
indic
textur
pattern
twotail
twosampl
equal
varianc
ttest
perform
mark
sampl
ns
mean
signific
indic
p
indic
p
chang
mutat
littl
effect
overal
chang
effici
turn
lead
slight
variat
effici
higher
slipperi
suggest
result
dual
site
rather
alon
replac
rare
cuu
codon
abund
cug
reduc
indic
second
slippag
due
hungri
fs
ustr
disrupt
frameshift
effici
higher
construct
slipperi
compar
nativ
sequenc
presum
secondari
structur
mrna
downstream
supplementari
figur
effect
disrupt
slipperi
site
decreas
frameshift
background
level
thu
support
lowlevel
fs
event
rescu
mutat
also
caus
nativ
sequenc
lead
prematur
termin
translat
show
mrna
oper
two
regim
one
caus
limit
uuaspecif
leutrna
isoacceptor
lead
ffr
product
anoth
ribosom
slip
trna
phe
trna
leu
transloc
slipperi
site
codon
yield
flr
product
switch
two
regim
modul
avail
uuaspecif
trna
leu
show
rare
cell
line
deriv
human
immun
cell
notion
support
vivo
experi
indic
limit
leu
cultur
media
lead
increas
e
coli
exact
effici
gagpol
mrna
differ
depend
type
model
system
phenomenon
note
attribut
differ
translat
rate
vivo
vitro
presum
presenc
bulk
aatrna
also
play
role
compar
figur
uaaspecif
leutrna
modul
effici
e
coli
mammalian
hybrid
translat
system
underscor
notion
frameshift
mechan
univers
conserv
ribosom
also
slip
aatrna
lack
aatrna
suppli
predomin
similarli
translat
e
coli
dnax
mrna
lead
slippag
aatrna
limit
suppli
case
dnax
switch
hungri
frameshift
may
caus
unfavor
condit
eg
amino
acid
starvat
contrast
use
pathway
constitut
due
inher
low
concentr
key
trna
uaa
leu
isoacceptor
relev
human
cell
fraction
normal
result
function
hiv
product
may
play
role
conjunct
transcript
slippag
revers
transcriptas
ratio
gag
gagpol
product
crucial
viru
propag
must
evolv
achiev
desir
effici
concentr
trna
uaa
leu
preval
human
cell
uua
codon
rare
human
genom
aend
codon
respect
cognat
trna
uaa
leu
significantli
underrepres
trna
pool
compar
trna
cag
leu
read
abund
cug
codon
figur
eukaryot
trna
express
tissuespecif
rel
express
trna
isoacceptor
tissu
show
statist
signific
correl
codon
usag
tissuespecif
gene
low
rel
abund
trna
uaa
leu
lymphocytederiv
cell
type
may
result
adapt
codon
usag
cell
hand
rare
uua
codon
account
leu
codon
lateexpress
gene
includ
gag
pol
express
late
hiv
gene
would
increas
demand
trna
uaa
leu
rare
respect
cell
may
delay
decod
uua
codon
includ
key
codon
slipperi
sequenc
deliveri
uua
codon
slipperi
site
slow
ribosom
switch
ffr
rout
lead
robust
codon
usag
dispar
hiv
human
host
util
disrupt
late
stage
viru
product
exampl
interferoninduc
antivir
protein
schlafen
select
abrog
express
late
viral
protein
codonusagedepend
manner
induc
specif
cleavag
trna
long
variabl
loop
includ
serin
leucin
trna
alreadi
rare
trna
trna
uaa
leu
reduc
trna
avail
might
manifest
ratelimit
step
synthesi
protein
involv
trna
trnadepend
modul
frameshift
also
report
within
expand
cag
stretch
huntingtin
gene
translat
expand
cag
repeat
mutant
huntingtin
exon
lead
deplet
charg
glntrna
cug
gln
pair
cag
codon
result
translat
frameshift
frameshift
frequenc
vari
strongli
among
differ
cell
line
higher
cell
intrins
lower
concentr
trna
cug
gln
emphas
biolog
signific
trna
concentr
modul
frameshift
effici
antihiv
therapi
proteas
inhibitor
lead
accumul
mutat
proteas
impair
recognit
specif
cleavag
site
allow
polyprotein
matur
mutat
proteas
secondari
mutat
aris
harbor
cleavag
site
gag
polyprotein
c
u
mutat
substitut
leu
phe
enhanc
van
der
waal
interact
substrat
mutant
proteas
therebi
increas
proteas
activ
mutat
produc
slipperi
sequenc
support
role
depend
sequenc
nativ
joint
activ
differ
alon
mutat
nonshifti
sequenc
c
u
mutat
suffici
support
level
may
suffici
viru
propag
find
allevi
detriment
effect
mutat
consist
previou
vitro
vivo
report
interestingli
antivir
therapi
drugresist
herp
simplex
virus
also
develop
unusu
slipperi
site
support
level
suffici
viru
replic
pathogen
despit
treatment
similarli
c
u
mutat
gagpol
mrna
modul
fs
effici
also
improv
activ
mutant
proteas
emerg
upon
proteas
inhibitor
treatment
evolutionari
pressur
led
conserv
known
sequenc
seem
allow
rapid
adapt
antivir
therapi
thu
constitut
use
differ
fs
regim
evolv
ensur
low
crucial
level
fs
requir
prolifer
